Manel Merabet
Chief Development Officer SKYMAB Biotherapeutics
Dr. Manel Kraiem Merabet is Chief Development Officer at Skymab, with over 11 years of experience in translational and clinical oncology research. Formerly a Scientific leader at Innate Pharma, she led ADC programs from target selection, lead optimization to IND and is regarded as an ADC expert. She is the patent inventor of several ADCs, including ADCs anti-GPCRs, IPH45, currently under clinical development. Dr. Merabet has served as Chair of multiple sessions, including the Linker Summit in Boston, the ANTIBODY and TIDES ADC Summit in Amsterdam, DDSS in Amsterdam, TMS Summit in London and 4th Annual GPCRs-Targeted Drug Discovery Summit. She holds a PharmD, a PhD in Oncology and Immunology, a European radiopharmacy–radiobiology degree from CEA Saclay, and a Master’s in Organic Chemistry from Saint Jerome University. She collaborates with leading biotech and pharma partners and has been recognized as an invited expert speaker at major ADC and oncology conferences, including the World ADC Summit.
Seminars
- Introducing Skylink as a next-generation, tumor-selective dual-payload linker platform designed to enhance ADC translational success
- Exploring high versatility of the platform, allowing flexible conjugation formats, DAR optimization, and integration of new payloads configurations
- Laying out translational data demonstrating improved PK/PD alignment, bystander activity, manufacturability features supporting progression toward IND-enabling studies
